Ipamorelin + CJC-1295 No DAC: Why Researchers Combine Them

Growth hormone secretion from the anterior pituitary is regulated by two primary signals: growth hormone-releasing hormone (GHRH), which stimulates GH release, and somatostatin, which inhibits it. A third regulatory input comes from ghrelin and synthetic ghrelin mimetics (growth hormone-releasing peptides, GHRPs), which act through the GHS-R1a receptor to amplify GH release independently of the GHRH pathway.

The physiological GH pulse results from the coordinated withdrawal of somatostatin tone and the arrival of GHRH signal. GHRPs amplify this pulse by adding a third stimulatory input. The combination of a GHRH analog plus a GHRP therefore targets two of the three regulatory inputs simultaneously, producing a synergistic rather than merely additive effect on GH secretion.

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide growth hormone secretagogue with a molecular weight of 711.85 Da. It was developed by Novo Nordisk in the 1990s as a selective GHS-R1a agonist. What distinguishes Ipamorelin from earlier GHRPs (such as GHRP-6 and GHRP-2) is its selectivity: it stimulates GH release with minimal effects on cortisol, prolactin, and aldosterone at effective GH-releasing doses.

This selectivity has been demonstrated in both animal models and human pharmacological studies. In healthy male volunteers, intravenous Ipamorelin at 1 mcg/kg produced significant GH release without measurable changes in ACTH, cortisol, or prolactin concentrations. This selectivity profile makes Ipamorelin the preferred GHRP for research protocols where confounding hormonal effects must be minimized.

CJC-1295 without Drug Affinity Complex (no DAC), also referred to as modified GRF(1-29) or mod-GRF, is a synthetic analog of the first 29 amino acids of human GHRH. The native GHRH(1-29) sequence is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) in plasma, with a half-life of approximately 5-7 minutes. CJC-1295 no DAC incorporates four amino acid substitutions (positions 2, 8, 15, and 27) that confer resistance to DPP-IV cleavage, extending the half-life to approximately 30 minutes.

The molecular weight of CJC-1295 no DAC is 3367.97 Da. It binds to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary, stimulating GH synthesis and secretion through a cAMP-dependent signaling cascade. Unlike the DAC-conjugated version (which has a half-life of approximately 8 days due to albumin binding), the no-DAC form produces discrete GH pulses rather than sustained elevation.

The rationale for combining Ipamorelin (GHRP) with CJC-1295 no DAC (GHRH analog) is grounded in the physiology of GH regulation. GHRH and GHRPs stimulate GH release through distinct receptor systems and intracellular signaling pathways. GHRH acts through the GHRH-R via cAMP/PKA signaling, while GHRPs act through GHS-R1a via IP3/DAG and calcium signaling.

When both pathways are activated simultaneously, the resulting GH release is synergistic — meaning the combined effect is greater than the sum of individual effects. This synergy has been demonstrated in multiple studies. Co-administration of GHRH and GHRP-6 in human subjects produced GH responses 2-3 times greater than predicted by simple addition of individual responses.

Ipamorelin has been studied in Phase 2 clinical trials for post-operative ileus recovery. In these studies, intravenous Ipamorelin was administered to patients following abdominal surgery to accelerate gastrointestinal recovery through GH-mediated mechanisms. The compound demonstrated acceptable safety profiles in these trials, though it did not achieve primary efficacy endpoints in all studies.

CJC-1295 (both DAC and no-DAC forms) has been studied in Phase 1 and Phase 2 clinical trials for growth hormone deficiency. The DAC-conjugated form demonstrated sustained GH and IGF-1 elevation in healthy subjects. Modified GRF(1-29) without DAC has been used extensively in research settings to study pulsatile GH dynamics due to its shorter half-life and more physiological release pattern.

The molecular basis for GHRH plus GHRP synergy involves convergent intracellular signaling in pituitary somatotrophs. GHRH binding to GHRH-R activates adenylyl cyclase, increasing intracellular cAMP and activating protein kinase A (PKA). GHRP binding to GHS-R1a activates phospholipase C, generating IP3 and DAG, which mobilize intracellular calcium stores and activate protein kinase C (PKC).

The PKA and PKC pathways converge on common downstream targets that regulate GH gene transcription and vesicle exocytosis. The simultaneous activation of both cascades produces a multiplicative effect on GH secretion. Additionally, GHRP signaling may reduce somatostatin tone, effectively removing the inhibitory brake on GH release at the same time GHRH is providing the stimulatory signal.

CJC-1295 with DAC (Drug Affinity Complex) includes a reactive lysine residue that forms a covalent bond with serum albumin after injection, extending the half-life to approximately 8 days. This produces sustained, non-pulsatile GH elevation. CJC-1295 without DAC has a half-life of approximately 30 minutes and produces discrete GH pulses that more closely mimic physiological secretion patterns.

Researchers studying pulsatile GH dynamics generally prefer the no-DAC form because it allows controlled, time-limited GH pulses that can be synchronized with the natural ultradian rhythm. The sustained elevation produced by the DAC form, while pharmacologically convenient, does not replicate physiological GH secretion and may trigger feedback mechanisms that blunt endogenous GH production over time.

Combination studies require careful experimental design. Minimum required groups include: vehicle control, Ipamorelin alone, CJC-1295 no DAC alone, and the combination. GH should be measured as area under the curve (AUC) over the secretory pulse rather than as a single time-point measurement, as the kinetics of the combined pulse differ from individual compound pulses.

Blood sampling frequency is critical — GH pulses peak within 15-30 minutes of administration, and infrequent sampling may miss peak values. Serial sampling at 5-10 minute intervals for the first 90 minutes post-administration provides adequate resolution for pharmacokinetic analysis.

Both peptides are supplied as lyophilized powders. Ipamorelin is reconstituted in bacteriostatic water at typical concentrations of 1-2 mg/mL. CJC-1295 no DAC follows similar protocols. Both should be stored at 2-8 degrees C after reconstitution and used within 3-4 weeks. Lyophilized powders are stable at minus 20 degrees C for extended periods.

If co-administration in the same solution is planned, compatibility testing is recommended. Both peptides are water-soluble at research concentrations, but pH shifts during mixing could affect stability. HPLC verification of the combined solution before experimental use confirms that neither compound has degraded.

Why not use GHRP-6 or GHRP-2 instead of Ipamorelin? GHRP-6 and GHRP-2 stimulate GH release effectively but also increase cortisol, prolactin, and appetite (via ghrelin pathway activation). Ipamorelin provides GH stimulation with minimal off-target hormonal effects, reducing confounding variables in research.

What is the difference between CJC-1295 with and without DAC? The DAC (Drug Affinity Complex) version binds to serum albumin, extending the half-life to approximately 8 days and producing sustained GH elevation. The no-DAC version has a 30-minute half-life and produces discrete, physiological-like GH pulses preferred for pulse-dynamics research.